Xia Ruolan, Zhou Yuwen, Wang Yuqing, Yuan Jiaming, Ma Xuelei
Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
West China School of Medicine, Sichuan University, Chengdu, China.
Front Oncol. 2021 Apr 12;11:633916. doi: 10.3389/fonc.2021.633916. eCollection 2021.
Hepatoid adenocarcinoma of the stomach (HAS) is a rare malignant tumor, accounting for only 0.17-15% of gastric cancers. Patients are often diagnosed at an advanced disease stage, and their symptoms are similar to conventional gastric cancer (CGC) without specific clinical manifestation. Morphologically, HAC has identical morphology and immunophenotype compared to hepatocellular carcinoma (HCC). This is considered to be an underestimation in diagnosis due to its rare incidence, and no consensus is reached regarding therapy. HAS generally presents with more aggressive behavior and worse prognosis than CGC. The present review summarizes the current literature and relevant knowledge to elaborate on the epidemic, potential mechanisms, clinical manifestations, diagnosis, management, and prognosis to help clinicians accurately diagnose and treat this malignant tumor.
胃肝样腺癌（HAS）是一种罕见的恶性肿瘤，仅占胃癌的0.17 - 15%。患者常被诊断为疾病晚期，其症状与传统胃癌（CGC）相似，无特异性临床表现。形态学上，HAC与肝细胞癌（HCC）具有相同的形态和免疫表型。由于其发病率低，这被认为在诊断中存在低估情况，并且在治疗方面尚未达成共识。与CGC相比，HAS通常表现出更具侵袭性的行为和更差的预后。本综述总结了当前文献和相关知识，以阐述其流行病学、潜在机制、临床表现、诊断、管理和预后，帮助临床医生准确诊断和治疗这种恶性肿瘤。
